GILD: Gilead Sciences

_Last updated 2026-10-30 10:00 ET from report. Screening/research, not investment advice._

Business

HIV (Biktarvy, Descovy, Yeztugo/lenacapavir), liver disease, oncology (Trodelvy, cell therapy). TRAI sector: Healthcare, cluster 3. Top ρ: BMY 0.61, PFE 0.59, ABBV 0.59, JNJ 0.58, AMGN 0.58.

Catalysts, guidance & news

• Q3 2026 (2026-10-29, 4:02 PM ET):
• Product sales $8.29B (+13%); ex-Veklury $8.2B (+16%).
• HIV ~$6.2B (+18%), Biktarvy ~$4.1B, Descovy ~$1.0B (+49%), Yeztugo $305M, Trodelvy $506M (+42%).
• Non-GAAP EPS $2.55 vs ~$2.17 consensus.
• Source: release via StockTitan; Business Wire; Investing.com.
• FY26 guide: product sales raised to $31.0–31.3B (from $30.1–30.4B). Non-GAAP EPS lowered to a loss of $(1.20)–(0.85) because of ~$12.4B of acquired IPR&D (Arcellx, Tubulis, Ouro, PepStar).
• Medicare: Biktarvy's Maximum Fair Price is effective 2028-01-01.

TRAI data

• 10-29: +4.03% to $165.61 into the print (z1d 2.28, relVol 1.44, rangePos 0.98). mean_reversion fade-short candidate, flagged by the postclose run after the release (S-071). After hours +2.17% ($169.20, 17:02).
• Last 4 prints: avg |gap| 1.68% (0.69 ATR), fill 50%, continuation 25%, day-1 in gap direction −0.68%. Replay has 0 MR trades entered into the name's own print.

Linkages

• See Business line (TRAI /api/correlations 60d to 2026-10-22, stale).

2026-10-30 09:00 update

• Premarket +4.76% (last print 08:35) vs 1.68% avg print gap (2.8×), after the 10-29 AMC beat-and-raise. Analysts raised targets overnight: Wells Fargo $190 (from $165), Needham $200, BMO $184, TD Cowen $175, Cantor $175 (Benzinga, 2026-10-30).
• The 8:53 premarket run still lists GILD as an MR fade-short (S-071 guard not built). Report call: skip. Proposals S-077 (skip big own-print gaps in a leading sector) and S-079 (/api/events shows next = null, n = 3: the 10-29 print is missing).

Report links

• 2026-10-29 17:00 — postclose movers & Friday gap risk
• 2026-10-30 09:00 — premarket rotation, INTC/crypto shocks, BMO prints

2026-10-30 10:00 update

• ~10:13 ET: +4.53% (OR30 +2.05…+6.06%, inside). Healthcare cluster 3 is bid across the board (LLY +4.1% day 2 after its beat-and-raise, BMY +3.0%, VRTX +2.8%, ABBV +1.8%). Fade-short: still skip (S-077). /api/events blind spot for AMC prints explained in S-079 revision.
• 10-29 AMC print (verified): adj. EPS $2.55 vs ~$2.17; revenue $8.3B vs ~$7.79B; FY26 product-sales guide $31.0–31.3B; +2.9% after hours (Gilead IR; Investing.com). At ~10:23: +4.20% vs XLV +1.10% and cluster-3 ex-LLY avg +1.75%, i.e. mostly idiosyncratic (report §10).
• 2026-10-30 10:00 — open follow-through, telecom/pharma bid, software split, events blind spot

2026-11-06 15:00 update — cluster-5 flat after Thu crush

• Thu −3.96%; Fri ~15:09 ~167.85 / ~+0.17%. SM Healthcare ×5 residual (suspended). Cluster 5; GILD–ABBV 0.73, GILD–VRTX 0.68, PFE–GILD 0.76.
• Thu crush: secondary post-earnings consolidation / profit-taking (TradingKey 11-05) [S]; no new Thu earnings reprint. Feeds S-149.
• Source: 2026-11-06 15:00 healthcare split.